Abstract
The role of aromatase inhibitors combined with gonadotropin-releasing hormone analog in metastatic male breast cancer patients remains unknown. In this retrospective study we evaluated the activity of letrozole combined with a gonadotropin-releasing hormone analog as a first- or second-line therapy for metastatic male breast cancer patients. 19 men entered the study. We did not observe any grade 3 or 4 adverse events. 2 patients (10.5 %) had complete response, 7 patients (36.8 %) experienced a partial response, 7 patients (36.8 %) had stable disease lasting ≥ 6 months, and 3 patients (15.8 %) had progressive disease. Overall, the disease control rate was 84.2 %. Median progression-free survival was 12.5 months (95 % CI 8.2-16.9), median overall survival was 35.8 months (95 % CI 24.4-49.2), 1- and 2-year survival rates were 89.5 and 67 %, respectively. Interestingly, 3 out of 4 patients treated with the combination following disease progression while on aromatase inhibitor monotherapy confirmed or improved the best overall response observed in the first-line setting. The combination of letrozole and gonadotropin-releasing hormone analog is effective and safe in hormone-receptor positive, metastatic male breast cancer patients.
MeSH terms
-
Aged
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Aromatase Inhibitors / administration & dosage
-
Breast Neoplasms, Male / drug therapy*
-
Breast Neoplasms, Male / radiotherapy
-
Breast Neoplasms, Male / surgery
-
Carcinoma, Ductal, Breast / drug therapy*
-
Carcinoma, Ductal, Breast / radiotherapy
-
Carcinoma, Ductal, Breast / secondary
-
Carcinoma, Ductal, Breast / surgery
-
Carcinoma, Papillary / drug therapy
-
Carcinoma, Papillary / surgery
-
Chemotherapy, Adjuvant
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Disease-Free Survival
-
Docetaxel
-
Epirubicin / administration & dosage
-
Estrogen Receptor Modulators / administration & dosage
-
Estrogens*
-
Fluorouracil
-
Gonadotropin-Releasing Hormone / agonists
-
Goserelin / administration & dosage
-
Humans
-
Kaplan-Meier Estimate
-
Letrozole
-
Male
-
Mastectomy, Modified Radical
-
Methotrexate
-
Middle Aged
-
Neoplasms, Hormone-Dependent / drug therapy*
-
Neoplasms, Hormone-Dependent / radiotherapy
-
Neoplasms, Hormone-Dependent / surgery
-
Nitriles / administration & dosage
-
Progesterone*
-
Radiotherapy, Adjuvant
-
Tamoxifen / administration & dosage
-
Taxoids / administration & dosage
-
Triazoles / administration & dosage
Substances
-
Antineoplastic Agents, Hormonal
-
Aromatase Inhibitors
-
Estrogen Receptor Modulators
-
Estrogens
-
Nitriles
-
Taxoids
-
Triazoles
-
Tamoxifen
-
Goserelin
-
Docetaxel
-
Gonadotropin-Releasing Hormone
-
Epirubicin
-
Progesterone
-
Letrozole
-
Cyclophosphamide
-
Fluorouracil
-
Methotrexate